Author

Panayiotis Anastasiou

The Francis Crick InstituteORCID 0009-0002-9894-0537Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:microscopy & imaging analysis· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrea de CastroiD· 2 shared Julian DownwardiD· 2 shared Míriam Molina‐ArcasiD· 2 shared Sareena RanaiD· 2 shared Alastair J. MagnessiD· 1 shared Alicia Alonso de la VegaiD· 1 shared Ania Mikolajczak· 1 shared Asher MullokandoviD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrea de CastroORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 27, 2025

Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumor cells

Mona Tomaschko, KangBo Ng, Christopher Moore…·Julian Downward

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

DOI 10.1101/2025.10.27.684825

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyScience AdvancesPeer-reviewedNov 1, 2024

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses

Megan Cole, Panayiotis Anastasiou, Claudia Lee…·Febe van Maldegem

The paper identifies regulatory T cells as mediators of resistance to KRAS-G12C inhibitors and anti-PD-1 therapy through spatial proteomic analysis of lung cancer models.

33 citationstop 3%

mouseproteomics

𝕏 PostBluesky